Liquidia Corporation reported a net income of $14.6 million for its fourth quarter of 2025, a turnaround from the $68.9 million net loss recorded for the full year. Adjusted EBITDA rose to $27.3 million, and cash and cash equivalents at year‑end climbed to $190.7 million, up from $176.5 million in December 2024, underscoring the company’s shift from a cash‑burning developer to a cash‑generating commercial business.
Total product sales for the year reached $148.3 million, driven almost entirely by YUTREPIA, the inhaled treprostinil platform launched in June 2025. In the fourth quarter alone, YUTREPIA generated $90.1 million in product sales, representing the bulk of the $92.0 million revenue reported for the quarter and a beat over the $87.5 million consensus estimate. YUTREPIA’s sales dominated both the pulmonary arterial hypertension and PH‑ILD markets, accounting for more than 100 % of market growth in Q4.
Compared with the prior year, Liquidia’s full‑year revenue jumped from $14.0 million in 2024 to $158.3 million in 2025, while SG&A expenses surged 93 % to $157.2 million, largely due to increased personnel, commercial, and legal costs. Gross profit margins remained strong at 89 %, reflecting pricing power in the specialty drug segment. The company’s net loss in 2024 of $128.3 million narrowed to $68.9 million in 2025, illustrating a clear trajectory toward profitability.
"Dr. Roger Jeffs, CEO, said, ‘YUTREPIA’s rapid adoption is one of the top specialty drug launches in recent years,’ highlighting the product’s market traction. Michael Kaseta, COO & CFO, added, ‘We ended the year with approximately $190.7 million in cash and cash equivalents, having generated $33 million of positive cash flow in the fourth quarter alone. Liquidia is now operating as a cash‑generating growth engine.’
The earnings miss on earnings per share—$0.15 versus the $0.19 consensus estimate—contributed to a 6.34 % drop in pre‑market trading, despite the revenue beat. The miss was largely due to higher SG&A costs, which offset the revenue upside and tempered earnings growth. Analysts noted that the EPS beat of $0.08 (the lower estimate) was insufficient to offset the higher cost base, leading to a muted market reaction.
Liquidia’s transition to profitability is supported by a robust cash position that will fund its L606 pipeline and market‑access expansion. The company’s proprietary PRINT particle‑engineering platform underpins YUTREPIA’s performance and positions it against competitors such as Tyvaso. Continued investment in the next‑generation inhaled treprostinil formulation and strategic commercial initiatives will be key to sustaining growth in the pulmonary hypertension market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.